Reply to E.A. Rakha et al

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1302-1303

  Wolff, Antonio C ^a   Elizabeth, M ^b   Hammond, H ^b   Hicks, David G ^c   Allison, Kimberly H ^d   Bartlett, John M S ^e   Bilous, Michael ^f   Fitzgibbons, Patrick ^g   Hanna, Wedad ^h   Jenkins, Robert B ⁱ   Mangu, Pamela B ^j   Paik, Soonmyung ^k   Perez, Edith A ^l   Press, Michael F ^m   Spears, Patricia A ⁿ   Vance, Gail H ^o   Viale, Giuseppe ^p   Dowsett, Mitch ^q   McShane, Lisa M ^r   Hayes, Daniel F ^s  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^f UNIVERSITY OF WESTERN SYDNEY   (Australia)

^g ST JUDE MEDICAL CENTER   (United States)

^h SUNNYBROOK RESEARCH INSTITUTE   (Canada)

ⁱ MAYO CLINIC   (United States)

^j AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^k National Adjuvant Breast and Bowel Project   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ NORTH CAROLINA STATE UNIVERSITY   (United States)

^o INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^p UNIVERSITY OF MILAN   (Italy)

^q ROYAL MARSDEN HOSPITAL   (United Kingdom)

^r NATIONAL CANCER INSTITUTE   (United States)

^s UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; BREAST TUMOR; FEMALE; GENETICS; ONCOLOGY; STANDARDS;

BREAST NEOPLASMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84927160708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7559     Document Type: Letter

References (15)

1. Rakha EA, Pigera M, Shaaban A, et al: National guidelines and level of evidence: Comments on some of the new recommendations in the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. J Clin Oncol 33:1301-1302, 2015
2. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138:241-256, 2014
3. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
4. Rakha EA, Ellis IO: Breast cancer: Updated guideline recommendations for HER2 testing. Nat Rev Clin Oncol 11:8-9, 2014
5. Dako: HerceptTest Interpretation Manual: Breast Cancer. http:// www.dako.com/28630-herceptest-interpretation-manual-breast-ihc-row.pdf
6. Vingiani A, Maisonneuve P, Dell'orto P, et al: The clinical relevance of micropapillary carcinoma of the breast: A case-control study. Histopathology 63:217-224, 2013
7. Arnedos M, Nerurkar A, Osin P, et al: Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20:1948-1952, 2009
8. Lebeau A, Turzynski A, Braun S, et al: Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 28:3264-3270, 2010
9. D'Alfonso T, Liu YF, Monni S, et al: Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: Emerging questions and considerations addressed. Am J Surg Pathol 34:575-581, 2010
10. Apple SK, Lowe AC, Rao PN, et al: Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 22:1151-1159, 2009
11. Chen X, Yuan Y, Gu Z, et al: Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: A meta-analysis. Breast Cancer Res Treat 134:957-967, 2012
12. Burge CN, Chang HR, Apple SK: Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 15:167-172, 2006
13. Lee AH, Key HP, Bell JA, et al: Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology 60:880-884, 2012
14. Shaaban AM, Purdie CA, Bartlett JM, et al: HER2 testing for breast carcinoma: Recommendations for rapid diagnostic pathways in clinical practice. J Clin Pathol 67:161-167, 2014
15. Wolff AC, Hammond ME, Hicks DG, et al: Reply to R. Bhargava et al and K. Lambein et al. J Clin Oncol 32:1857-1859, 2014